{"title":"Clinical Study of Bullous Pemphigoid With Oral Mucosal Symptoms After Oral Administration of Dipeptidyl Peptidase-4 Inhibitors.","authors":"Yuria Akira, Masaki Minabe, Sari Ueno, Junichiro Inada, Nana Morita, Kentaro Izumi, Takeshi Nomura, Michiyoshi Kouno","doi":"10.1111/1346-8138.70507","DOIUrl":"https://doi.org/10.1111/1346-8138.70507","url":null,"abstract":"<p><p>Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used for diabetes treatment. However, reports of DPP-4 inhibitor-associated bullous pemphigoid (BP) have been increasing. This study examined 12 cases of BP with oral mucosal lesions associated with DPP-4 inhibitor therapy. Six cases presented with only oral mucosal lesions, while the other six patients had non-inflammatory skin lesions. Discontinuation of DPP-4 inhibitors led to symptom improvement in nine cases, whereas three cases did not improve, with lesion progression to the pharynx. Remission was achieved after a mean of 20.8 ± 24.6 months after DPP-4 inhibitor discontinuation, but two cases relapsed. Anti-BP180 NC16a antibodies were positive in six cases, while full-length BP180 ELISA was positive in 8 of 10 tested cases. These findings suggested that DPP-4 inhibitor-associated BP frequently involves oral mucosal lesions, and some cases may present solely with mucosal symptoms. Given the potential for recurrence and severe progression, long-term follow-up is essential.</p>","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149149189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Non-Pharmacological Psychosomatic Approaches to Patients With Atopic Dermatitis: A Delphi Consensus of Expert Opinions in Japan.","authors":"Masako Minami-Hori, Hideaki Hasuo, Takashi Yamakita, Makoto Hashiro, Yoshinobu Matsuda, Hiromichi Matsuoka, Yasunari Asano, Masanori Mori, Nobuyuki Sudo","doi":"10.1111/1346-8138.70523","DOIUrl":"https://doi.org/10.1111/1346-8138.70523","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by persistent itch and a prolonged clinical course and can affect mental health and impair quality of life. Stress and anxiety exacerbate the symptoms of itch, leading to a vicious cycle that influences patient scratching behaviors and worsens disease prognosis. Dermatologists should consider psychosomatic correlations in patients with AD and provide psychosomatic intervention. However, standardized, consensus-based non-pharmacological psychosomatic approaches for patients with AD have not been established in Japan. This study sought to establish a Japanese consensus on non-pharmacological psychosomatic approaches to patients with AD. Japanese experts in psychosomatic dermatology stated their level of agreement with 28 items in round 1 plus one added in round 2 (29 items in total) regarding psychosomatic approaches as non-pharmacological approaches among patients with AD over Delphi rounds. Consensus was defined a priori as agreement from ≥ 75% of participants. The response rate was 17/21 (81.0%) in the first round and 17/17 (100%) in the second round. Twenty-five statements were adopted over both rounds. Performance of medical interviews and physical examinations, recognition of patient efforts, and respect for the interpretive model of the patient categorized to establish a good therapeutic relationship showed agreement. Evaluation of pathology from physical and psychological perspectives (addictive scratching, building a bio-psycho-social [BPS] model and pathophysiological hypothesis) showed high-level agreement. Indirectly promoting patient awareness of aggravating factors of AD and sharing the BPS model and pathophysiological hypothesis with the patient showed consensus. Further, 14 statements about the application of psychosomatic correlations to therapy showed agreement. In the second round, group therapy also gained consensus as a useful intervention. Our Delphi panel provides recommendations about psychosomatic interventions for patients with AD to standardize approaches in clinical practice and research.</p>","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149121327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Case of Systemic Keratotic Disorders With Bark-Like Appearance on the Dorsal Aspects of Both Feet.","authors":"Kenta Morimoto, Sumire Ishino, Ken Watanabe","doi":"10.1111/1346-8138.70526","DOIUrl":"https://doi.org/10.1111/1346-8138.70526","url":null,"abstract":"","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149121112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to \"Incidence Trends and Severe in-Hospital Outcomes of Pemphigus Vulgaris: A Nationwide Cohort Study\".","authors":"","doi":"10.1111/1346-8138.70501","DOIUrl":"10.1111/1346-8138.70501","url":null,"abstract":"","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":"1555"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149019371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sweet Syndrome Solely Localized to the Periocular Region in a Patient With Chronic Myelogenous Leukemia Treated With Dasatinib.","authors":"Ryo Kondo, Toshihisa Hamada, Tetsuo Toyama, Taro Akatsuka, Daisuke Suzuki, Mina Komuta, Yuichiro Hayashi, Takayuki Shiomi, Tomoaki Nakaseko, Makoto Sugaya","doi":"10.1111/1346-8138.70451","DOIUrl":"10.1111/1346-8138.70451","url":null,"abstract":"","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":"e864-e865"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148681859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}